CAJ | 학술논문

背景：氟尿嘧啶缓释剂是目前常用的抗肿瘤缓释药物，具有良好的抗肿瘤作用。目的：探讨氟尿嘧啶缓释剂在进展期胃癌治疗中的作用效果。 　　方法：应用文献检索的方法获取氟尿嘧啶缓释剂在胃癌治疗中应用的相关研究文献，对符合研究标准的文献进行深入的数据分析，文章选取氟尿嘧啶缓释剂预防肿瘤根治切除后复发和转移进行研究，对临床应用氟尿嘧啶缓释剂植入腹腔治疗的患者进行观察随访，通过观察患者的症状和体征、肿瘤标记物的表达变化、肿瘤组织的大小以及生存率等，明确氟尿嘧啶缓释剂在进展期胃癌治疗中的应用效果。 　　结果与结论：进展期胃癌患者治疗中应用氟尿嘧啶缓释剂联合动脉灌注化疗辅助治疗后，患者的症状改善程度及肿瘤切除率明显提高，患者血清中肿瘤指标物CEA、CA19-9、CA72-4显著降低，肿瘤切除前后病理学比较显示化疗后肿瘤细胞的凋亡及坏死程度明显增加。应用氟尿嘧啶缓释剂还能够降低肿瘤局部转移和复发，提高患者生存率。
배경：불뇨밀정완석제시목전상용적항종류완석약물，구유량호적항종류작용。목적：탐토불뇨밀정완석제재진전기위암치료중적작용효과。 　　방법：응용문헌검색적방법획취불뇨밀정완석제재위암치료중응용적상관연구문헌，대부합연구표준적문헌진행심입적수거분석，문장선취불뇨밀정완석제예방종류근치절제후복발화전이진행연구，대림상응용불뇨밀정완석제식입복강치료적환자진행관찰수방，통과관찰환자적증상화체정、종류표기물적표체변화、종류조직적대소이급생존솔등，명학불뇨밀정완석제재진전기위암치료중적응용효과。 　　결과여결론：진전기위암환자치료중응용불뇨밀정완석제연합동맥관주화료보조치료후，환자적증상개선정도급종류절제솔명현제고，환자혈청중종류지표물CEA、CA19-9、CA72-4현저강저，종류절제전후병이학비교현시화료후종류세포적조망급배사정도명현증가。응용불뇨밀정완석제환능구강저종류국부전이화복발，제고환자생존솔。
BACKGROUND:Fluorouracil sustained-release agent is a commonly used anti-cancer sustained-release drug, which has a good anti-tumor effect. OBJECTIVE:To explore the effect of fluorouracil sustained-release agent in the treatment of gastric cancer. METHODS:Literatures concerning the effect of fluorouracil sustained-release agent in the treatment of gastric cancer were retrieved and analyzed. In the paper, we investigated the preventive effect of fluorouracil sustained-release agent against tumor recurrence and metastasis after radical resection, and fol owed up the patients who underwent clinical peritoneal implantation of fluorouracil sustained-release agent. We could determine the effect of fluorouracil sustained-release agent in the treatment of advanced gastric cancer by observing the patient’s symptoms and signs, expression of tumor markers, tumor size and survival rate. RESULTS AND CONCLUSION:After combination therapy of fluorouracil sustained-release agent and arterial infusion chemotherapy adjuvant therapy, the patient’s symptoms and tumor resection rate were significantly improved. The levels of CEA, CA19-9, CA72-4 in the serum of patients significantly reduced, while the apoptosis and necrosis of tumor cells significantly increased. Fluorouracil sustained-release agent could also reduce tumor metastasis and local recurrence, and improve patient survival.